Faes Farma Stock

Faes Farma Equity

The The Equity of Faes Farma (FAE.MC) as of Aug 3, 2026 is 744.80 M EUR. In the previous year, The Equity was 725.87 M EUR — a change of 2.61% (higher).

Equity

744.80 MEUR

YoY

2.61%

Last updated:

In 2026, Faes Farma's equity was 744.80 M EUR, a 2.61% increase from the 725.87 M EUR equity in the previous year.

Access this data via the Eulerpool API

Faes Farma Stock analysis

What does Faes Farma do? The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market. Faes Farma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Faes Farma's Equity

Faes Farma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Faes Farma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Faes Farma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Faes Farma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Faes Farma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Faes Farma stock

The Equity of Faes Farma is 744.80 M EUR in 2026.

The Equity of Faes Farma changed from 725.87 M EUR to 744.80 M EUR, representing a 2.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Faes Farma since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Faes Farma historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Faes Farma

All Key Metrics — Faes Farma